Showing results (1-10 of 371) with videos related to
Sort By:
Pageof 38
Cancer Journal (Sudbury, Mass.)|November 26, 2019
Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic LeukemiaR Andrew Harkins, Sharvil P Patel, Christopher R FlowersExpert Review of Pharmacoeconomics & Outcomes Research|October 19, 2019
Cost burden of diffuse large B-cell lymphomaR Andrew Harkins, Sharvil P Patel, Christopher R FlowersClinical Lymphoma, Myeloma & Leukemia|February 18, 2020
Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell LymphomaSharvil P Patel, R Andrew Harkins, Michelle J Lee, et al.Expert Review of Hematology|September 13, 2019
Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphomaR Andrew Harkins, Andres Chang, Sharvil P Patel, et al.Cancer|May 30, 2020
Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphomaMichelle J Lee, Jean L Koff, Jeffrey M Switchenko, et al.Expert Review of Vaccines|June 5, 2007
BiovaxID idiotype vaccination: active immunotherapy for follicular lymphomaChristopher R FlowersPharmacoeconomics|June 26, 2004
The role of cost-effectiveness analysis in the era of pharmacogenomicsChristopher R Flowers, David VeenstraCurrent Oncology (Toronto, Ont.)|May 27, 2025
Patient-Reported Outcome Measures (PROMS) in LymphomaNeha Akkad, Christopher R FlowersClinical Lymphoma, Myeloma & Leukemia|December 16, 2010
A decade of progress in lymphoma: advances and continuing challengesChristopher R Flowers, James O ArmitageBlood|January 9, 2016
Identifying risk factors for B-cell lymphomaChristopher R Flowers, Christine F SkibolaPageof 38